ICRC-Weyer is a consultancy and All-Phase CRO specializing in the design and delivery of individual solutions for complex projects, from critical sections of submission dossiers for novel products to data rescue of legacy studies, and from biostatistics for adaptive phase I/II umbrella protocols to 100% medical review on pivotal phase III studies. The functional service portfolio focuses on expert data and writing services, including biostatistics, data management, medical and pharmacovigilance/safety writing, as well as medical review/continuous medical data auditing services for all stages of the clinical development process, development and methodological consulting, and specialist support in the post-marketing setting. The company, with offices located in Germany, was founded in 1993 and is owner-managed in the second generation. The diverse and international core team of 25 consultants brings together skills, outlooks, and experiences from various backgrounds in industry and academia.
It is this breadth of perspectives and the high value placed on intellectual flexibility and an open exchange within the team, with clients, partners, and experts that drives the creative design and meticulous implementation of tailored solutions, placing ICRC-Weyer at the critical juncture of being both small enough to care for, yet big enough to cope with highly individual and extremely complex projects. Together with the company's experience in working with both big and small pharmaceutical companies, biotechs, medical device manufacturers, and individual researchers and the specific needs of these different clients, it has also allowed the company to build comprehensive expertise in diverse areas on demand, resulting in a broad spectrum of therapeutic areas (from a core of oncology, autoimmune diseases and neurology/psychiatry, to niches such as hormonal contraception, degenerative eye diseases, or pulmonary hypertension) and types of projects supported (from clinical studies of phases I-IV, to non-interventional studies and registers, and from database migrations to overarching pharmaco- and device vigilance activities, especially aggregate reporting).